Johnson & Johnson is mobilizing resources
of its Janssen Pharmaceutical Companies in response to the outbreak to develop a possible preventive vaccine candidate against SARS-CoV-2, leveraging Janssen's AdVac® and PER.C6® technology, that provide the ability to rapidly upscale production of the optimal vaccine candidate. These are the same technologies that were used in the development and manufacturing of Janssen's investigational Ebola vaccine, which is currently deployed in the Democratic Republic of the Congo
, and were also used to construct the Company's Zika, RSV
The Company announced on February 18, 2020 that Janssen Pharmaceutical Companies will expand its existing partnership with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health & Human Services, to seek treatment solutions for COVID-19.
Johnson & Johnson has robust business continuity plans in place across its global supply chain network to prepare for unforeseen events like the coronavirus outbreak. We are closely monitoring product demand and supply levels across our global network to ensure adequate and effective distribution, and working diligently to meet patient, customer and consumer need.